Price movement over the last 24 hours
Airbnb, Inc. vs Novartis AG — how do they compare? Airbnb, Inc. trades at $142.83 (market cap $88.31B), while Novartis AG trades at $155.41 (market cap $298.98B). The key difference: Novartis AG is far larger — about 3.4× Airbnb, Inc.'s market cap, and Novartis AG pays a 3.02% dividend while Airbnb, Inc. pays none. Which is the better fit depends on your goals.
| ABNB | NVS | |
|---|---|---|
Market Cap | $88.31B | $298.98B |
Sector | Consumer Cyclical | Health |
52-Week High | $148.93 | $168.62 |
52-Week Low | $111.54 | $113.50 |
Enterprise Value | $78.84B | $339.00B |
Dividend Yield | — | 3.02% |
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) trades at $148.80, showing minimal daily movement with a slight decline of 0.09%. The stock maintains a bullish technical outlook with strong moving average signals and trades near pivot point resistance at $149. Fundamentally, the company demonstrates robust profitability with 82.9% gross margins and 19.9% net income margin, though recent quarters have seen earnings misses against expectations. Revenue growth continues with 2025 reaching $12.24 billion, supported by the company's asset-light model and global travel recovery.
The investment case balances strong fundamentals against valuation concerns, with a P/E of 36.5 suggesting premium pricing. Analyst consensus remains positive with a $161.80 price target, though recent earnings misses and CEO stock sales warrant monitoring. Key risks include travel demand sensitivity, competitive pressures, and execution of new initiatives like hotel expansion and AI development. The stock offers growth exposure to travel recovery but requires careful valuation assessment.
Novartis (NVS) trades at $157.03, down 1.79% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $56.67B revenue, 23.92% net margin, and robust cash flow generation. Recent developments include multiple strategic acquisitions and regulatory approvals expanding the oncology pipeline, though earnings have shown volatility with two misses in the last four quarters.
NVS presents a balanced investment case with strong profitability and pipeline expansion offset by valuation concerns and earnings inconsistency. The stock offers stability through defensive healthcare exposure but faces execution risks from integration challenges and competitive pressures in pharmaceutical markets.
Trailing returns across standard periods
Latest headlines on both assets
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →